CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

Note: This grant page has been archived and is very likely out of date.

Deadline: The deadline for this grant has passed

Grant amount: Up to US $450,000

Fields of work: Environmental Chemistry & Toxicology Emergency Medical Care & Services Health & Medicine Pharmacology

Applicant type: Government Entity, Nonprofit, For-Profit Business, Indigenous Group

Funding uses: Research

Location of project: United States

Location of residency: United States


This Funding Opportunity Announcement (FOA) solicits applications for the early-stage development of therapeutics to mitigate the adverse health effects resulting from toxic chemical exposure. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include specific chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The overall scope of this solicitation includes validation of therapeutic targets and preclinical characterization of lead compounds. The UG3 phase of this FOA supports target validation and characterization of initial lead compound(s); UH3 phase activities include candidate optimization and in vivo demonstration of activity and efficacy in relevant post-exposure models. At the conclusion of the overall UG3/UH3 funding period, projects are expected to deliver at least one well-characterized therapeutic candidate.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

Other Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

This page was last reviewed July 08, 2022 and last updated July 08, 2022